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. . .the cataracts of heaven set open on the earth. . .
—John Milton (1)
ometimes we envy our fathers and grandfathers. With few
xceptions, what they had learned in medical school was
oing to remain the essence of their medical profession
hroughout their lives. They seldom had to face almost
omplete revolutions in their approach to patient manage-
ent. We are not so lucky, or perhaps we are—given the
rue excitement and intellectual stimulation provided by the
udden opening of a new world. I refer to the dramatic
mpact that molecular biology is having on those who try to
e good doctors, or up-to-date investigators, in these rapidly
hanging times.
See page 2570
The identification of the first few genes for ion channel
iseases, and I use the long QT syndrome (LQTS) as a
ood example of an arrhythmic disorder of genetic origin,
hich also represents the best paradigm of a direct bridge
etween molecular biology and clinical cardiology, provided
he initial shock (2–4). All of a sudden, it became old
ashioned to talk of LQTS instead of, more properly, LQT1
r LQT2 or LQT3. Within a few months we learned of
ifferential responses in the duration of the QT interval to
eart rate changes according to the gene involved and that
e had, unknowingly, entered the era of gene-specific
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iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ute for Cardiovascular Research, Department of Medicine, University of Cape Town,a
ape Town, South Africa; and the Department of Family and Community Medicine,
ollege of Medicine, King Saud University, Riyadh, Saudi Arabia.herapy because the sodium-channel blocker mexiletine had
een proposed as a possible means to antagonize the delayed
ntry of sodium current in cardiac cells (5).
Within a few years, we were also first told that risk
tratification is influenced by the genes involved (6) and
hen that prognosis depends not only on the gene but also
n the location of the mutation (7). As if this were not
nough, we were taught to find out the effect produced by
he various mutations on the repolarizing currents because
his could imply mild or severe clinical phenotypes (8), and
hortly afterward, we were told that this was true, but not
lways, because there were relatively common disease-
ausing mutations producing severe manifestations not ex-
lained by cellular electrophysiology, thus opening the
hasm of mutation-specific risk stratification (9).
Even our management had to be adapted to the specific
enes involved. We had to make different recommendations
n terms of lifestyle, more or less in the following way. “You
re an LQT1 patient: don’t run, don’t swim, don’t get
xcited.” “You are an LQT2 patient: don’t keep the tele-
hone and the alarm clock in your bedroom, and tell your
other to wake you up gently in the morning without
creaming that you are late for school.” “You are an LQT3
atient: don’t sleep.” All this because someone had demon-
trated a rather tight gene-specific relationship between
ertain triggers and life-threatening cardiac events (10).
hat was not enough. Even our good old beta-blockers were
o longer equally effective for all LQTS patients. Everyone
greed that they are extremely effective for LQT1 patients
10–12), but a little bit less for LQT2 patients (10,12). As
o LQT3, we became very confused. First, we were told that
hese patients may have too many therapeutic failures with
eta-blockers (10,12) and then that all of these patients
hould receive an implantable cardioverter-defibrillator no
atter what (13), and now it seems that beta-blockers can
e reasonably effective if these patients had no cardiac events
n the first year of life (14).
The saga continues. In this issue of the Journal, Hofman
t al. (15) from Amsterdam tell us that it is not enough to
etermine that a patient is affected by LQTS or by another
rimary arrhythmia syndrome such as catecholaminergic
olymorphic ventricular tachycardia (CPVT) or the Bru-
ada syndrome (BrS). They tell us, rather forcefully, that
nce the proband has been successfully genotyped, we
hould track down the entire family and genotype all family
embers. Are they out of their minds?
In one word: no. In a few words, they are absolutely right.
et us see what they did and why they are right.
What they did was relatively straightforward. They iden-
ified a pathogenic mutation in 100 probands affected by
QTS, CPVT, or BrS. Through them, they identified 509
elatives who were genotype positive. After a visit, the
robands and relatives received a host of information on
hings to do (e.g., prevent or correct low serum potassium)
nd things to avoid (list of drugs never to be used). In many
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Cascade Screening to Prevent Sudden Death June 8, 2010:2577–9ases, mostly for LQTS (65%) and CPVT (71%), they
eceived therapy. This happened seldom for the family
embers of BrS patients (6%). Even though it is not
ossible to assess the benefit of this approach, the authors
re probably correct when they say that in all likelihood a
umber of life-threatening episodes have been averted. The
uthors also conclude that a large number of carriers of
isease-causing mutations have thus initiated treatment
efore any symptom, something that would have not hap-
ened without genetic testing, because they, with a normal
r borderline phenotype, would have not been identified.
he authors are essentially right, and their paper is an
mportant one. It is not revolutionary because many of us
ith experience in dealing with primary arrhythmia syn-
romes have been doing exactly the same thing for several
ears, but it sends a message that physicians with less
pecific experience with these highly-specific disorders
hould listen carefully to.
The concept of cascade screening does not come out of
he blue. Its origin lies in the evidence (16) that the
ypothesis presented in 1980, which proposed that there
ust have been some patients affected by LQTS and
onetheless with a normal QT interval (17), was indeed
orrect. The demonstration of low penetrance in LQTS
16) implied that normal findings on an electrocardiogram
ould not be used to exclude LQTS. This, in turn, implied
he necessity to perform molecular screening in all family
embers once the disease-causing mutation had been iden-
ified in the proband.
Let us leave aside the problem of the family members
ho have a phenotype (e.g., QT prolongation) that allows a
apid diagnosis. For these patients, screening with a simple
lectrocardiogram is usually sufficient for a first diagnosis.
he concept of a full cascade screening allows the identifi-
ation, as mutation carriers, of individuals who otherwise
ould have been considered as unaffected and therefore
ould have remained at risk, either because of a spontane-
us event or more likely because of the exposure to certain
rugs. Also very important is the fact that those family
embers who are found not to be mutation carriers will
njoy the relief of knowing that they are not at risk and that
hey should not fear for their offspring.
How important is it to make cascade screening routine in
he management of patients affected by one of the primary
rrhythmia syndromes? What are the implications of its
mplementation or of the lack of it?
Let us use again LQTS as the best primary arrhythmia
xample, for the simple reason that it is the one for which
ore data are available. The prevalence of LQTS is now
nown, based on actual data, and is close to 1 in 2,000 live
irths (18). This allows for the first time quantification of
ow many new cases of LQTS can be expected every year.
ur prospective study of neonatal electrocardiography in
44,000 one-month-old infants, complemented by molec-
lar screening whenever the QT interval was markedly
rolonged, has demonstrated that 51% of the family mem- fers were also mutation carriers, as one would expect
ealing with an autosomal dominant disease (18). Thus,
ascade screening will identify a significant number of
ndividuals at risk.
Hofman et al. (15) noted that, at variance with LQTS
nd CPVT, the identification of family members affected by
rS very seldom led to the institution of a preventive
herapy. This is not difficult to explain. Whereas prevention
f life-threatening arrhythmias in LQTS and CPVT can be
one with beta-blockers, and such a treatment is generally
ell accepted by the patients, for BrS, the current thera-
eutic options are either doing nothing or placing an
mplantable cardioverter-defibrillator, a truly stark choice.
ot surprisingly, most asymptomatic BrS patients are re-
uctant to take such a big step. In this regard, many
ardiologists and patients alike will probably welcome the
ew option, which we fully endorse, proposed by Viskin
t al. (19), namely, to randomize in an open study asymp-
omatic BrS patients to either no treatment or to empirical
uinidine. The study is open to all those interested and
etails can be found online (20). We do not know whether
his attempt will be successful, but the interest for it reflects
he sad reality of the tormenting doubts that we all have
hen facing a young asymptomatic BrS patient without
lements for an adequate risk stratification, given the grow-
ng perplexities surrounding the positive predictive value of
he electrophysiologic study (21). The proposal by Viskin et
l. (19) has merit independently of what its outcome will be.
t is a hypothesis worth testing. If successful, the BrS
atients identified by cascade screening will face less scary
herapeutic options.
The effectiveness of cascade screening for the early
dentification of affected family members also carries med-
colegal implications at 2 levels. Cascade screening requires
ositive genotyping of the proband because identification of
he disease-causing mutation is the necessary first step.
herefore, at the first level, it follows that the physician who
oes not attempt to genotype the proband, affected by a
rimary arrhythmia syndrome, has willfully decided to
gnore whether some of his or her family members are
arriers of the disease and thereby exposed to the risk of
ife-threatening arrhythmias. Also, at the second level, the
hysician who, after having obtained positive genotyping,
oes not initiate cascade screening within the family of the
roband has similarly willfully decided to leave the affected
amily members—and it is important to remember that they
ill be approximately one-half of those of first-degree
elatives—uninformed about their status and unprotected.
ot performing cascade screening will unavoidably lead to a
umber of avoidable deaths. This is the magnitude of the
mpact that genetic screening is having on clinical cardiol-
gy: true cataracts.
Hofman et al. (15) have not done something unique or
specially original. But having reported, in good detail, their
xperience in the management of these patients and of their
amilies represents a major contribution because it takes out
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June 8, 2010:2577–9 Cascade Screening to Prevent Sudden Deathf our small club knowledge that needed to be shared with
ardiologists practicing everywhere. Cascade screening will
elp to avoid currently widespread errors in the manage-
ent of arrhythmogenic disorders of genetic origin. Specif-
cally, it will help to reduce the number of avoidable deaths
mong the silent mutation carriers, family members of
ffected patients. This will be achieved partly by therapy,
henever appropriate, partly by providing on a regular basis
n updated list of drugs to carefully avoid, and possibly also
y lifestyle changes. Cascade screening is one of the more
orceful demonstrations that molecular biology and genetics
re not just a tool for researchers, but represent an important
nd by now essential component of good medical care.
eprint requests and correspondence: Dr. Peter J. Schwartz,
epartment of Cardiology, University of Pavia, c/o Fondazione
RCCS Policlinico San Matteo, Viale Golgi, 19, 27100 Pavia,
taly. E-mail: peter.schwartz@unipv.it.
EFERENCES
1. Milton J. Paradise Lost. 2nd edition. London, England: S. Simmons,
1674.
2. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with
an inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80:
805–11.
3. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED,
Keating MT. A molecular basis for cardiac arrhythmia: HERG
mutations cause long QT syndrome. Cell 1995;80:795–803.
4. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel
potassium channel gene: KVLQT1 mutations cause cardiac arrhyth-
mias. Nat Genet 1996;12:17–23.
5. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients
with mutations of the SCN5A and HERG genes have differential
responses to Na channel blockade and to increases in heart rate.
Implications for gene-specific therapy. Circulation 1995;92:3381–6.
6. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the
long-QT syndrome. N Engl J Med 2003;348:1866–74.
7. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic
events in long-QT syndrome with mutations in the pore region of the phuman ether-a-go-go-related gene potassium channel. Circulation
2002;105:794–9.
8. Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1
long-QT syndrome by location, coding type, and biophysical function
of mutations involving the KCNQ1 gene. Circulation 2007;115:
2481–9.
9. Crotti L, Spazzolini C, Schwartz PJ, et al. The common long-QT
syndrome mutation KCNQ1/A341V causes unusually severe clinical
manifestations in patients with different ethnic backgrounds: toward a
mutation-specific risk stratification. Circulation 2007;116:2366–75.
0. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype
correlation in the long-QT syndrome: gene-specific triggers for life-
threatening arrhythmias. Circulation 2001;103:89–95.
1. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta-
blockers in long QT syndrome type 1: contribution of non-compliance
and QT prolonging drugs to the occurrence of beta-blocker treatment
“failures.” Circulation 2009;119:215–21.
2. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT
syndrome loci and cardiac events among patients treated with beta-
blockers. JAMA 2004;292:1341–4.
3. Etheridge SP, Sanatani S, Cohen MI, Albaro CA, Saarel EV, Bradley
DJ. Long QT syndrome in children in the era of implantable
defibrillators. J Am Coll Cardiol 2007;50:1335–40.
4. Schwartz PJ, Spazzolini C, Crotti L. All LQT3 patients need an ICD.
True or false? Heart Rhythm 2009;6:113–20.
5. Hofman N, Tan HL, Alders M, van Langen IM, Wilde AAM. Active
cascade screening in primary inherited arrhythmia syndromes: does it
lead to prophylactic treatment? J Am Coll Cardiol 2010;55:2570–6.
6. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the
long-QT syndrome: clinical impact. Circulation 1999;99:529–33.
7. Schwartz PJ. The long QT syndrome. In: Kulbertus HE, Wellens HJJ,
editors. Sudden Death. The Hague, the Netherlands: M Nijhoff,
1980:358–378.
8. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the
congenital long-QT syndrome. Circulation 2009;120:1761–7.
9. Viskin S, Wilde AA, Tan HL, et al. Empiric quinidine therapy for
asymptomatic Brugada syndrome: time for a prospective registry.
Heart Rhythm 2009;6:401–4.
0. Empiric Quinidine for Asymptomatic Brugada Syndrome. Available
at: http://www.brugadasyndrome.info/. Accessed May 3, 2010.
1. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of
patients diagnosed with Brugada syndrome: results from the FINGER
Brugada Syndrome Registry. Circulation 2010;121:635–43.
ey Words: cardiogenetics y follow-up y inherited arrhythmias y
rophylactic treatment.
